Alkem Labs Ne Di Offer! Swiss Heart Device Firm Occlutech Ko Kharidne Ka Plan, Players Chaukanna!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Alkem Labs Ne Di Offer! Swiss Heart Device Firm Occlutech Ko Kharidne Ka Plan, Players Chaukanna!
Overview

Alkem Laboratories ne ek bada strategic move kiya hai! Apni subsidiary Alkem Medtech ke zariye, inone Swiss heart device firm Occlutech Holding AG mein **51-55%** stake buy karne ka binding offer diya hai. Isse Alkem cardiovascular devices ke advanced segment mein enter karega. Lekin ek catch hai: Occlutech FY2024 mein **EUR 20.52 million** ( **₹185.73 Cr** ) ka net loss report kiya hai, aur negative net worth bhi hai.

Okay, toh Alkem Laboratories ne ek serious step liya hai! Unki wholly-owned subsidiary Alkem Medtech Private Limited ne Swiss company Occlutech Holding AG mein majority stake, matlab 51% se lekar 55% tak, khareedne ka ek binding offer de diya hai. Ye deal Alkem ko seedha cardiovascular devices ke specialized aur fast-growing business mein le jaegi, jo ki pharma se thoda alag area hai. Deal all-cash mein ho rahi hai.

Ab baat karte hain Occlutech ki, jise Alkem khareedne ka soch raha hai. Haan, unki revenue toh lagatar badh rahi hai. FY2022 mein EUR 31.84 million se lekar FY2023 mein EUR 36.24 million aur FY2024 mein EUR 43.95 million (jo lagbhag ₹397.80 Crore banta hai) tak pahunch gayi hai.

Lekin, yahan ek bada "but" hai. Financials dekho toh FY2024 mein company ko EUR 20.52 million (approx ₹185.73 Crore) ka bada net loss hua hai. Aur 31st December 2024 tak, company ka net worth negative EUR 3.58 million (around ₹31.93 Crore) tha. Matlab, liabilities assets se kaafi zyada hain. Aage FY2025 ke liye bhi figures dekho toh revenue EUR 49.38 million ( ₹487.87 Cr ) hone ki ummeed hai, EBITDA EUR 2.10 million ( ₹20.79 Cr ) ka hai, par net loss EUR 6.85 million ( ₹67.65 Cr ) tak ka rehne ka anuman hai.

Is deal se Alkem kya leverage karega? Woh Occlutech ki global presence, unke distribution network, aur minimally invasive cardiac implants ke product portfolio ka fayda uthana chahte hain. Unki nazar congenital heart defects, stroke prevention, aur heart failure jaise areas par hai jismein kaafi potential hai.

Risk Factor: Sabse bada challenge yahi hai ki ek loss-making company jiska net worth negative hai, usko turn around karna. Alkem ko ekdum solid strategy chahiye hogi profitabilité badhane ke liye. Integration ka risk bhi hai, alag-alag countries aur regulations mein operations ko manage karna. Aur haan, yeh market kaafi competitive bhi hai.

Investors abhi deal finalize hone ka wait karenge, valuation dekhenge, aur Alkem ki strategy ko follow karenge ki woh is naye segment mein kaise grow karte hain.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.